New oversubscribed $21 million convertible debt instrument ("New Debt") refinances all outstanding convertible debt, provides $6.5 million in new capital for working capital and general corporate purposes does not accrue interest and converts into common shares at $6.00 per share Automatic Exchange provision automatically converts the New Debt into Preferred Stock upon the effectiveness of a registration statement and attainment of shareholder approval for the creation of Preferred Stock The class of Preferred Stock that the New Convertible Debt exchanges into (the "Funding Preferred") converts into common shares at $50.00 per share New funds raised satisfy capital raising closing condition from Fully Binding Term Sheet with Datavault AI, EOS Technology Holdings, Scilex Pharma and HealthBridge Advisors TAMPA, FL / ACCESS Newswire / May 27, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™ , today announced that it completed a financing transaction through the issuance of a new $21 million convertible debt instrument (the "New Debt") that refinances all of its outstanding convertible debt and provides $6.5 million in fresh capital (the "New Money"). The offering was oversubscribed.